title: Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
abstract: OBJECTIVE
  This multicenter phase III study compared the MEMID regimen (mitoxantrone, VP16, methylglyoxal, ifosfamide and dexamethasone) with CEOP, a CHOP-like regimen (cyclophosphamide, epirubicin, vincristine and prednisone), in elderly patients (> or =65 years) with aggressive non-Hodgkin's lymphoma (NHL).
  
  
  METHODS
  One hundred and forty-nine patients were eligible, 72 in the MEMID arm and 77 in the CEOP arm. The primary endpoint was to compare overall survival (OS) between groups, and secondary endpoints were event-free survival (EFS), response rate and toxicity.
  
  
  RESULTS
  Neutropenia (p < 10(-5)), anemia (p < 10(-5)) and thrombocytopenia (p = 0.0006) were significantly more frequent in patients who received MEMID. We observed an objective response rate of 55.5% in the MEMID arm and 64.9% in the CEOP arm (p = 0.24). The median OS and EFS were 15.4 and 8.5 months in the MEMID arm, and 20.3 and 10.5 months in the CEOP arm (p = 0.59 and 0.47), respectively. The median EFS was 15.4 months in the MEMID arm and 20.3 months in the CEOP arm (p = 0.59).
  
  
  CONCLUSIONS
  The increased toxicity without survival benefit confirms the superiority of CHOP and CHOP-like regimens for elderly patient with aggressive NHL.
authors.affiliation: Centre Antoine-Lacassagne, Nice, France.
authors.forename: E
authors.initials: E
authors.lastname: Chamorey
authors.forename: R
authors.initials: R
authors.lastname: Gressin
authors.forename: F
authors.initials: F
authors.lastname: Peyrade
authors.forename: J F
authors.initials: JF
authors.lastname: Rossi
authors.forename: G
authors.initials: G
authors.lastname: Lepeu
authors.forename: C
authors.initials: C
authors.lastname: Foussard
authors.forename: J L
authors.initials: JL
authors.lastname: Harrousseau
authors.forename: M
authors.initials: M
authors.lastname: Fabbro
authors.forename: B
authors.initials: B
authors.lastname: Richard
authors.forename: V
authors.initials: V
authors.lastname: Delwail
authors.forename: H
authors.initials: H
authors.lastname: Maisonneuve
authors.forename: J P
authors.initials: JP
authors.lastname: Vilque
authors.forename: A
authors.initials: A
authors.lastname: Thyss
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D009503:Neutropenia / Q000139:chemically induced; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D011765:Pyruvaldehyde / Q000008:administration & dosage; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D015251:Epirubicin; D014750:Vincristine; D005047:Etoposide; D011765:Pyruvaldehyde; D003907:Dexamethasone; D003520:Cyclophosphamide; D008942:Mitoxantrone; D007069:Ifosfamide; D011241:Prednisone